EMA Authorised: Rivastigmine Hexal (rivastigmine) — Hexal AG

View source ↗

Summary

Hexal AG's rivastigmine product has been authorized in the EU for dementia-related indications including Alzheimer's disease and Parkinson's disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Dementia
• Parkinson Disease

Drugs mentioned

• Rivastigmine Hexal (rivastigmine)

Snippet

Status: Authorised. Therapeutic area: Dementia;Alzheimer Disease;Parkinson Disease. MAH: Hexal AG. Decision date: 15/01/2026